Omnicare Receives Court Approval for Sale of Business to GenieRx
Rhea-AI Summary
Omnicare, a CVS Health (NYSE: CVS) subsidiary, received U.S. Bankruptcy Court approval to sell its business to GenieRx Holdings, a partnership of Milrose Capital and Integro Healthcare Services. The transaction is expected to close later in 2026, pending regulatory approval and customary closing conditions.
Omnicare plans to continue delivering pharmacy services, emphasizing transparent pricing, clinically aligned programs, and a compliance-first approach throughout the court-supervised process.
Positive
- Bankruptcy Court approves sale of Omnicare business to GenieRx Holdings
- Transaction expected to close later in 2026, pending regulatory approvals
- Omnicare to continue pharmacy services and support for skilled nursing and assisted living clients during transition
Negative
- Closing remains subject to regulatory approval and customary closing conditions
- Omnicare continues to operate under a court-supervised bankruptcy process until completion of the sale
News Market Reaction – CVS
In the May 14 session, CVS declined 0.98%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Earnings beat, guidance | Positive | +7.7% | Strong Q1 2026 results and raised full-year EPS and cash flow guidance. |
| May 05 | Formulary changes | Positive | -1.6% | Biosimilar adoption and formulary updates aimed at affordability and access. |
| Apr 24 | Operational streamlining | Positive | -1.2% | Progress simplifying prior authorization and reducing provider administrative burden. |
| Apr 08 | Provider survey results | Positive | +0.7% | Survey highlighting provider optimism and opportunities to simplify care. |
| Apr 06 | Earnings call notice | Neutral | -0.3% | Scheduling notice for upcoming Q1 2026 earnings conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive, but price reactions have been mixed, with strong alignment on earnings and more variable responses to operational or policy updates.
Over recent months, CVS has highlighted multiple operational and financial milestones. On May 6, Q1 2026 earnings showed strong revenue and EPS, with raised full‑year guidance and a +7.65% reaction. Earlier news focused on biosimilar adoption, simplifying prior authorization, and provider sentiment, with modest and sometimes negative short‑term price moves. Against this backdrop, the court‑approved sale of Omnicare reflects ongoing portfolio and operational optimization alongside solid core performance.
Key Terms
U.S. Bankruptcy Court regulatory
proof of claim regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
"Today's approval marks an important milestone. We are entering this next phase with clarity on what matters most: delivering reliable pharmacy services, maintaining safe and clinically appropriate care, and being transparent and fair in how we operate," said David Azzolina, President of Omnicare. "Our teams continue to show a deep commitment to our customers, and I am grateful for the work they do every day to support residents in skilled nursing and assisted living settings."
With GenieRx, Omnicare will have the opportunity to strengthen its service—by staying disciplined in operations, aligning closely with clinical best practices, and working in partnership with the providers and communities that count on Omnicare. Leading up to the closing of the transaction, Omnicare will continue to support its clients with transparent pricing, clinically aligned programs and data‑driven insights, as well as a partnership‑driven approach for all communities it serves.
"GenieRx's investment in Omnicare is a testament to the strength of their platform and their impressive employee culture and commitment to putting patients and customers first," said Rowan Farber, CEO of Integro Healthcare Services. "We admire the trust Omnicare has earned with its customers over decades of serving skilled nursing and assisted living partners, and we look forward to working collaboratively with their team to continue building on that strong foundation and legacy. Together, we share a commitment to delivering reliable service, clinical expertise, and continuity of care to the patients and communities who depend on it most."
The transaction is expected to close later this year, subject to regulatory approval and customary closing conditions. Until the transaction closes, Omnicare's priorities remain unchanged. The business remains focused on working closely with customers and delivering safe, reliable pharmacy services. That includes maintaining a strong compliance-first approach in all aspects of operations, supporting residents with higher acuity, and continuing to improve billing management, delivery, and communication for operators and residents.
Additional Information About the Court-Supervised Sale Process
Additional information regarding Omnicare's court-supervised process is available at www.OmnicareRestructuring.com.
Court filings and other information related to the proceedings, including bidding procedures and instructions on how to file a proof of claim, are available on a separate website administered by Omnicare's claims agent, Stretto, at https://cases.stretto.com/Omnicare, by calling Stretto representatives toll-free at (833) 570-5323 or (949) 276-9547 for calls originating outside of the
Advisors
Jenner & Block LLP and Haynes Boone are serving as legal counsel, Houlihan Lokey is serving as investment banker and Alvarez & Marsal is serving as restructuring advisor to Omnicare.
About Omnicare
Omnicare is a national leading provider of pharmacy services to the long-term care market, which includes skilled nursing facilities and independent and assisted living communities, addressing the needs of an aging population across the continuum of senior care.
For more information, visit https://www.omnicare.com/.
About CVS Health
CVS Health® is a leading health solutions company simplifying health care one person, one family and one community at a time. As of March 31, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 88 million plan members. The Company also serves an estimated more than 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
Media Contacts
Omnicare
Aaron Palash
212-355-4449
OmnicareMedia@joelefrank.com
CVS Health
Ethan Slavin
860-273-6095
Ethan.Slavin@CVSHealth.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/omnicare-receives-court-approval-for-sale-of-business-to-genierx-302771461.html
SOURCE CVS Health